PDX models

 

 

Patient-derived tumor xenograft panels enhance the power of preclinical assays by :

 

  • Faithfully reproducing the biological features of human cancers in term of histology, genomics and proteomics
  • Providing established concordance between patient and xenograft drug responses
  • Covering molecular diversity of clinical disease
  • Allowing identification of responsive cancer types
  • Allowing biomarker exploratory studies for subsequent patient stratification

 

 

PDX collection

 

 

Cancer Type Subtypes
Breast TNBC, HER2+, ER+, PR+
Colorectal
Lung NSCLC, SCLC
Prostate Primary hormone-dependent, Hormone-independent variant
Brain Glioblastoma
Kidney Renal Cell Carcinoma (RCC)
Pancreas
Skin Melanoma, Merkel cell carcinoma
Ovary
Endometrium
Liposarcoma
Pediatric liver tumors Hepatoblastoma, Rhabdoid tumor

PDX database content

 

 

 

 

Molecular database

 

  • gene sequences (NGS Illumina HiSeq technology)
  • manually currated gene mutation data
  • gene expression profiles (U133plus Affy)
  • copy number variarion data (SNP6.0 Affy)
  • miRNA expression data (miRNA array)
  • protein expression (markers)

 

 

Drug Response data

 

  • PDX response to conventional treatments

 

 

Patient data (on a case-by-case basis)

 

  • histology
  • treatment before surgery
  • disease stage

 

Tumor surgical samples are obtained with patient’s consent, grafted subcutaneously into immunodeficient mice and maintained by serial transplantations.
Xenografts are considered established after 3 passages and frozen stocks are made at low passages.